Latest

The Targeted Pulse: Don’t Miss the FDA’s Latest Treatment Decisions and What a Retrospective Study Revealed in Endometrial Cancer

Capivasertib combination shows promise in mHSPC vs the placebo combination, LBS-007 received fast track designation, and RP1 plus nivolumab submitted a BLA application. We also cover a retrospective study seeking to identify factors related in delayed care in endometrial cancer and belantamab mafodotin’s BLA application was accepted by the FDA.

Read More »